弓建华   肿瘤室   副研究员   硕士生导师

教育背景及工作经历：

2007-至今 中国医学科学院医药生物技术研究所 肿瘤室 副研究员

2012-2014 美国犹他州立大学, 生化系, 博士后

2004-2007 协和医科大学，微生物与生化药学专业，博士

2001-2004 山西医科大学，生理学专业，硕士

1996-2001 山西医科大学，临床医学专业，学士

主要研究方向：肿瘤精准靶向治疗、抗肿瘤药物研发、药物递送系统

专业研究领域：

以肿瘤精准靶向治疗药物研发为核心，具体分为以下四个研究方向：

1. 新抗肿瘤药发现与分子药理：开展新型抗肿瘤小分子的筛选与鉴定，系统解析药物与靶点的分子互作机制及相关信号通路调控规律，同步开展体外及体内抗肿瘤活性评价。

2. 抗体偶联药物：开展特异性靶向抗体筛选与表征，进行连接子（linker）的设计、制备新型药物偶联物，开展体外细胞毒性检测与体内靶向分布及抑瘤效果验证。

3. 放射性核素偶联药物：设计放射性核素与靶向分子的特异性偶联体系，系统评估药物在体内的分布代谢特征及靶向抗肿瘤活性。

4. 基因工程化生物膜囊泡递送系统：构建基因工程改造的生物膜囊泡递送载体，优化囊泡的制备工艺，提升囊泡对药物/基因的负载效率及靶向修饰的特异性。

代表性论文：

(1) G. Wang, L. Zheng, X. Yang, X. Wang, Z. Zhou, Y. Kan, W. Wang*, J. Gong*, J. Yang*, Novel ImmunoPET Probes [(64)Cu]Cu-NOTA-GGB02-F9 for Small-Cell Lung Cancer Derived from a SEZ6-Targeting Antibody, J Med Chem, 69 (2026) 2968-2975.

(2) L. Zheng, X. Yang, J. Liu, G. Wang, Z.A. Zhou, Y. Xu*, J. Gong*, J. Yang*, Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas, J Med Chem, 2025；68(23):25607-25615.

(3) Xian-Yu Zhu#,*, Ling-Li Gao#, Yan-Bo Zheng, Peng-Fei Zhao, Han-Rui Wei, Rui-Xue Liu, Li-Ping Zhao, Jun-Yi Zhang, Qi Sun, Ling-Ling Zheng, Han Lv*, Ji-Gong Yang*, Jian-Hua Gong*, Zheng-Chang Wang, Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy, Adv Healthc Mater , 2025: e2405229.

(4) Xu Yang#, Jun Liu, Cui-Cui Li, Ling-Ling Zheng, Xia Lu, Ziang Zhou, Xianyu Zhu, Jian-Hua Gong*, Qing-Fang Miao*, Ji-Gang Yang*, Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma, Eur J Nucl Med Mol Imaging, 2025 ;52(5):1751-1763.

(5) Ling-Ling Zheng#, Cui-Cui Li, Xu Yang, Jun Liu, Guang-Yun Wang, Ziang Zhou, Xian-Yu Zhu*, Jian-Hua Gong*, Ji-Gang Yang*, GD2-targeted theranostics of neuroblastoma with [(64)Cu]Cu/[(177)Lu]Lu-hu3F8, Eur J Nucl Med Mol Imaging, 2025;52(5):1764-1777.

(6) L. Gao, H. Wei, J. Zhang, Y. Zheng, J. Zhang, Y. Zheng, J. Yang, J. Gong, Utilization of Neutrophil Elastase Tetrapeptide Substrate as a Linker Agent for Anti-GD2 Antibody Drug Conjugates, Bioconjug Chem, (2025).

(7) Yong-Hua Liu #,*, Jun-Yi Zhang #, Jia-Qi Tian # , Cheng-Xi Wang , Tian-Qi Wang , Jian-Hua Gong *, Lai-Xing Hu *. Structure-activity relationship study of new carbazole sulfonamide derivatives as anticancer agents with dual-target mechanism. Eur J Med Chem, 2024, 273:116509.

(8) Jun-Yi Zhang# , Shu-Xuan Li# , Yi-Jiang Zheng ,Ling-Li Gao, Han-Rui Wei , Yu-Jing Li，Yong-Hua Liu*, Yan-Bo Zheng Y*, Jian-Hua Gong *, Novel pyridazinone derivatives bind to KSRP: Synthesis, anti-tumor biological evaluations and modelling insights, Eur J Med Chem, 2024, 278:116811.

(9) Xing Lv # , Wei-Hua Cheng # , Xiao-Xue Li ,Hai Shang , Jun-Yi Zhang, Han-Yu Hong , Yi-Jia Zheng, Yan-Qun Dong , Jian-Hua Gong *,Yan-Bo Zheng *, Zong-Mei Zou *. Dual inhibition of topoisomerase II and microtubule of podophyllotoxin derivative 5p overcomes cancer multidrug resistance, Eur J Pharmacol ,2024, 983:176968.

(10) Xian-Yu Zhu#,*, Ling-Ling Zheng#,, Peng-Fei Zhao, Ling-Li Gao, Liang Wang, Jun Liu, Xu Yang, Han-Rui Wei, Ming-Yu Zhang, Liang Yan, Han Lv*, Jian-Hua Gong*, Ji-Gang Yang*, Zhen-Chang Wang, Fe/Cu Bimetallic Nanozyme Co-Assembled with (177)Lu and Tanshinone for Quadruple-Synergistic Tumor-Specific Therapy, Adv Healthc Mater, 2024: e2402696.

授权专利：

1. 郑艳波；弓建华;李育净;郑毅佳;洪菡雨;张均怡;高漫;魏菡锐;甄永苏。一种抗CD24抗体及其应用。授权日期：20251209. CN119899266B

2. 弓建华;郑艳波;高伶俐;张均怡;魏菡锐;董艳群;一种抗Claudin18.2单克隆抗体及其应用, 授权日：2025-11-21, CN202311558985.5

3. 弓建华;郑艳波;刘秀均;甄永苏;李毅;一种治疗肿瘤的复合物及其制剂和用途, 申请日：2020-3-24, CN202010213016.6

4. 郑艳波;弓建华;甄永苏;刘秀均;李毅;司书毅;硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用, 申请日：2020-3-20, CN202010203050.5

联系电话：010-63024341

电子邮箱： ann_gong@imb.pumc.edu.cn